ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shailender Bhatia, Andrew Scott Brohl, Isaac Brownell, Sunandana Chandra, Sumia Dakhil, Marc S. Ernstoff, Leslie Anne Fecher, Ted Gooley, Glenn J. Hanna, Reina Hibbert, Ciara Marie Kelly, Samantha M. Kiriluk, Paul Nghiem, Vivian Nguyen, Nichole Pelz, Aubrey A. Poisson, Katharine Andress Rowe Price, Vernon K. Sondak, John A. Thompson, Scott S. Tykodi
Institutions: University of Washington, Fred Hutch Cancer Center, Moffitt Cancer Center, National Cancer Institute, Northwestern University, Roswell Park Comprehensive Cancer Center, University of Michigan, Dana-Farber Cancer Institute, Seattle Cancer Care Alliance, Memorial Sloan Kettering Cancer Center, Mayo Clinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2892235917